CTOs on the Move

MyoKardia

www.myokardia.com

 
Our Mission: Change the world for patients with cardiovascular disease through bold and innovative science. MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus: treatment of heritable cardiomyopathies, a group of genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We are a growing community of employees who enjoy working with and learning from each other. We collaborate in a way that ensures the growth of the company as well each employee ...
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.myokardia.com
  • 333 Allerton Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.741.0900

Executives

Name Title Contact Details

Funding

MyoKardia raised $46M on 05/01/2015

Similar Companies

MicroGEM

At MicroGEM, we are transforming the landscape of DNA and RNA extraction. Come see how our single-tube extraction workflows can work for you!

Vium

Vium is the first company to create a living informatics platform for preclinical in vivo drug research.

Statistical Center for HIV/AIDS Research and Prevention

Statistical Center for HIV/AIDS Research and Prevention is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

F1 Oncology

We are harnessing the power of the immune system to target some of the most challenging solid tumor malignancies.

Metacrine

We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical scaffold with the potential to be best-in-class for non-alcoholic steatohepatitis, or NASH, and first- in-class for Inflammatory Bowel Disease, or IBD. In addition to our FXR program, we have continued to invest in drug discovery on other therapeutic targets that have effects on inflammation and/or fibrosis for which we believe we could develop proprietary small molecule therapies.